KYNB

Kyntra Bio Inc

5.24

Oct 21 • 12:37 PM ET -0.04 (-0.76%)

Healthcare Biotechnology USA Nano NASD

Peers: NXTC STRO VERU CTMX PYXS KAPA MGNX TLX AKTS IRON

Index	-
Market Cap	21.22M
Enterprise Value	-48.10M
Income	130.71M
Sales	4.62M
Book/sh	-7.44
Cash/sh	22.55
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	34
IPO	Nov 14, 2014

P/E	0.16
Forward P/E	-
PEG	-
P/S	4.59
P/B	-
P/C	0.23
P/FCF	-
EV/EBITDA	-
EV/Sales	-10.41
Quick Ratio	2.59
Current Ratio	2.69
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	32.31
EPS next Y	-9.86
EPS next Q	-3.55
EPS this Y	-119.09%
EPS next Y	-13.78%
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	-64.23% -48.42%
EPS Y/Y TTM	6280.60%
Sales Y/Y TTM	-91.38%
EPS Q/Q	257.26%
Sales Q/Q	-209.35%
Earnings	Aug 13 AMC
EPS/Sales Surpr.	192.96% -171.78%

Insider Own	7.21%
Insider Trans	0.00%
Inst Own	24.67%
Inst Trans	-1.02%
ROA	-22.15%
ROE	-
ROIC	-
Gross Margin	1.65%
Oper. Margin	-1088.33%
Profit Margin	2830.95%
SMA20	-13.32%
SMA50	-25.34%
SMA200	-27.86%
Trades

Shs Outstand	4.05M
Shs Float	3.76M
Short Float	2.66%
Short Ratio	5.12
Short Interest	0.10M
52W High	11.65 -55.02%
52W Low	4.85 8.04%
Volatility	7.72% 5.82%
ATR (14)	0.37
RSI (14)	29.28
Beta	1.04
Rel Volume	0.61
Avg Volume	19.55K
Volume	7,408

Perf Week	-5.84%
Perf Month	-28.02%
Perf Quarter	-25.88%
Perf Half Y	-27.12%
Perf YTD	-40.32%
Perf Year	-53.00%
Perf 3Y	-61.88%
Perf 5Y	-98.02%
Perf 10Y	-98.80%
Recom	1.33
Target Price	36.80
Prev Close	5.28
Price	5.24
Change %	-0.76%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-13-26	Initiated	Maxim Group	Buy	$35
Jul-07-26	Initiated	Oppenheimer	Outperform	$35
Jun-09-26	Initiated	Rodman & Renshaw	Buy	$30
Aug-08-23	Downgrade	BofA Securities	Neutral → Underperform	$4 → $2
Jun-26-23	Downgrade	William Blair	Outperform → Mkt Perform
Jun-26-23	Downgrade	Stifel	Buy → Hold
Jun-26-23	Downgrade	Raymond James	Outperform → Mkt Perform
Jun-26-23	Downgrade	BofA Securities	Buy → Neutral
Jun-02-23	Upgrade	Stifel	Hold → Buy	$23 → $32
Jan-31-23	Upgrade	William Blair	Mkt Perform → Outperform
Jan-26-23	Upgrade	Raymond James	Mkt Perform → Outperform	$35
Jan-05-23	Upgrade	BofA Securities	Neutral → Buy	$18 → $27
Sep-22-21	Downgrade	Goldman	Neutral → Sell	$16 → $11
Aug-20-21	Upgrade	Raymond James	Underperform → Mkt Perform
Jul-16-21	Downgrade	Stifel	Buy → Hold	$55 → $29
Jul-16-21	Downgrade	BofA Securities	Buy → Neutral	$29
Apr-07-21	Downgrade	Mizuho	Buy → Neutral	$72 → $29
Apr-07-21	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-31-21	Upgrade	BofA Securities	Neutral → Buy	$47
Mar-02-21	Downgrade	Jefferies	Buy → Hold	$75 → $45

Show Previous Ratings

Oct-01-26 07:00AM	Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors (GlobeNewswire)
Sep-02-26 07:30AM	Kyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire) +7.30%
Aug-31-26 04:05PM	Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation (GlobeNewswire)
Aug-17-26 03:02PM	Kyntra Bio Inc (KYNB) (Q2 2026) Earnings Call Highlights: Advancing FG-3246 and Roxadustat with ... (GuruFocus.com)
Aug-13-26 04:32PM	Kyntra Bio: Q2 Earnings Snapshot (Associated Press)
04:02PM	Loading…
04:02PM	Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
Aug-06-26 09:00AM	Kyntra Bio to Report Second Quarter 2026 Financial Results (GlobeNewswire)
Jun-11-26 04:05PM	Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes (GlobeNewswire) +5.47%
May-12-26 03:07AM	Kyntra Bio Inc (KYNB) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic Advances ... (GuruFocus.com) +6.25%
May-11-26 04:28PM	Kyntra Bio: Q1 Earnings Snapshot (Associated Press)
04:05PM	Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
May-04-26 04:05PM	Kyntra Bio to Report First Quarter 2026 Financial Results (GlobeNewswire)
Apr-08-26 04:05PM	Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire) +5.49%
Mar-16-26 11:00PM	Kyntra Bio Inc (KYNB) Q4 2025 Earnings Call Highlights: Navigating Revenue Decline with ... (GuruFocus.com) +5.29%
04:20PM	Kyntra Bio: Q4 Earnings Snapshot (Associated Press Finance)
04:02PM	Loading…
04:02PM	Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Mar-09-26 05:20PM	Septerna, Inc. (SEPN) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +7.31%
10:00AM	Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
07:00AM	Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Feb-24-26 08:27AM	What's Going On With Kyntra Bio Stock Tuesday? (Benzinga) -9.57%
Feb-23-26 05:10PM	Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026 (GlobeNewswire)
Feb-17-26 04:05PM	Kyntra Bio to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.28%
Jan-21-26 12:13PM	What sets FGEN apart? Diversification, ESG and growth opportunities - FGEN P5 (Proactive)
12:06PM	Where FGEN sees growth beyond wind and solar - FGEN P4 (Proactive)
11:54AM	Inside FGENs inflation-linked income and dividend strategy - FGEN P3 (Proactive)
Jan-07-26 07:30AM	FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum (GlobeNewswire) +7.65%
Dec-15-25 07:00AM	Roxadustat Granted Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes by the U.S. Food and Drug Administration (GlobeNewswire) +19.81%
Dec-02-25 04:05PM	FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit (GlobeNewswire) -5.28%
Nov-11-25 12:04AM	FibroGen Inc (FGEN) Q3 2025 Earnings Call Highlights: Strategic Moves Bolster Financial ... (GuruFocus.com) -9.64%
Nov-10-25 06:00PM	FibroGen (FGEN) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:58PM	Loading…
04:58PM	FibroGen: Q3 Earnings Snapshot (Associated Press Finance)
04:02PM	FibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Nov-03-25 04:02PM	FibroGen to Report Third Quarter 2025 Financial Results (GlobeNewswire)
Sep-24-25 07:00AM	FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer (GlobeNewswire)
Sep-02-25 07:00AM	FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million (GlobeNewswire)
Aug-27-25 04:02PM	FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire) +6.20%
Aug-18-25 07:00AM	FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation (GlobeNewswire) +19.01%
Aug-12-25 03:07AM	FibroGen Inc (FGEN) Q2 2025 Earnings Call Highlights: Strategic Moves and Cost Reductions ... (GuruFocus.com) +10.51%
Aug-11-25 06:55PM	FibroGen (FGEN) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
06:10PM	FibroGen: Q2 Earnings Snapshot (Associated Press Finance)
04:02PM	FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Aug-07-25 07:00AM	FibroGen Announces Positive Type C Meeting with the FDA for Roxadustat in Patients with Anemia Associated with Lower-Risk Myelodysplastic Syndromes (GlobeNewswire) +11.75%
Aug-04-25 04:02PM	FibroGen to Report Second Quarter 2025 Financial Results (GlobeNewswire)
Jun-12-25 04:02PM	FibroGen Announces 1-for-25 Reverse Stock Split (GlobeNewswire) -14.46%
Jun-09-25 04:02PM	FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors (GlobeNewswire)
May-13-25 07:52AM	Q1 2025 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents)
03:10AM	FibroGen Inc (FGEN) Q1 2025 Earnings Call Highlights: Strategic Moves and Cost Management Amid ... (GuruFocus.com)
May-12-25 05:15PM	FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:13PM	FibroGen: Q1 Earnings Snapshot (Associated Press Finance)
04:02PM	FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-08-25 07:50AM	Stevanato Group (STVN) Q1 Earnings and Revenues Top Estimates (Zacks)
May-05-25 04:05PM	FibroGen to Report First Quarter 2025 Financial Results (GlobeNewswire) -8.46%
Apr-02-25 04:05PM	FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-28-25 07:00AM	FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology (GlobeNewswire)
Mar-18-25 08:26AM	Q4 2024 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents) -21.80%
03:02AM	FibroGen Inc (FGEN) Q4 2024 Earnings Call Highlights: Navigating Revenue Declines with ... (GuruFocus.com)
Mar-17-25 04:28PM	FibroGen: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-03-25 04:45PM	FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire) -6.78% -5.33%
Feb-20-25 04:02PM	FibroGen sells China unit to AstraZeneca for $160m (Pharmaceutical Technology) +37.44% -8.61%
06:40AM	AstraZeneca boosts China presence with FibroGen's anemia drug in $160 million deal (Reuters)
06:30AM	FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million (GlobeNewswire)
05:55AM	AstraZeneca deepens China presence with FibroGen deal (BioPharma Dive)
Dec-16-24 08:05AM	FibroGen Appoints David DeLucia as Chief Financial Officer (GlobeNewswire)
Nov-13-24 10:22AM	Q3 2024 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents) -14.07%
02:21AM	FibroGen Inc (FGEN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Cost Reductions (GuruFocus.com)
Nov-12-24 06:10PM	FibroGen (FGEN) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +14.18%
05:06PM	FibroGen: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	FibroGen Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-04-24 04:05PM	FibroGen to Report Third Quarter 2024 Financial Results (GlobeNewswire) -5.65%
Oct-09-24 05:09PM	FibroGen Inc (FGEN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Shifts (GuruFocus.com)
Sep-16-24 01:32AM	Duchenne muscular dystrophy: major trials and events to watch in 2023 (Clinical Trials Arena)
Sep-03-24 04:05PM	FibroGen to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -9.19% +20.36%
Aug-06-24 06:15PM	FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
05:10PM	FibroGen: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-31-24 11:54AM	FibroGen axes 75% of staff after lead cancer therapy fails in Phase III trials (Pharmaceutical Technology) -47.56%
07:33AM	Vertexs pain drug gets speedy FDA review; Keytruda hits a sales milestone (BioPharma Dive)
Jul-30-24 04:07PM	FibroGen to Report Second Quarter 2024 Financial Results (GlobeNewswire) -8.04%
04:05PM	FibroGen Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies and Provides Corporate Update (GlobeNewswire)
Jun-18-24 08:00AM	FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Cancer on June 26, 2024 (GlobeNewswire)
Jun-12-24 10:22AM	Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments (PR Newswire)
Jun-04-24 07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
Jun-03-24 04:05PM	FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO in Upcoming Clinical Trials (GlobeNewswire)
04:02PM	FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors (GlobeNewswire)
09:17AM	Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates (PR Newswire)
07:00AM	FibroGen to Present at Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-28-24 06:10AM	7 Penny Biotech Stocks to Triple Your Investment (InvestorPlace)
May-23-24 05:05PM	FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting (GlobeNewswire)
May-07-24 10:15AM	FibroGen, Inc. (NASDAQ:FGEN) Q1 2024 Earnings Call Transcript (Insider Monkey) +18.10%
08:57AM	Q1 2024 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents)
07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:36AM	Top Premarket Gainers (MT Newswires)
07:00AM	FibroGen to Participate in Upcoming Investor Conferences (GlobeNewswire)
03:14AM	FibroGen Inc (FGEN) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-06-24 08:58PM	FGEN Stock Earnings: FibroGen Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:25PM	FibroGen: Q1 Earnings Snapshot (Associated Press Finance)
04:02PM	FibroGen Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-29-24 07:00AM	FibroGen to Report First Quarter 2024 Financial Results (GlobeNewswire)
Apr-24-24 04:02PM	FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting (GlobeNewswire) -8.01%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wettig Thane	CEO	Nov 17 '25	Buy	9.10	2,700	24,570	24,939	Nov 17 04:42 PM
Wettig Thane	CEO	Nov 13 '25	Buy	9.18	1,000	9,180	22,239	Nov 17 04:42 PM

Kyntra Bio, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.

CEO & DirectorMr. Thane Wettig

Senior VP & CFOMr. David DeLucia

Corporate Secretary & General CounselMr. John Alden

Head of People and Culture & Executive DirectorMs. Michelle Simonetti

Chief Medical OfficerDr. Carrie Brownstein M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KYNB

Kyntra Bio Inc

Upgrade your Finviz experience